Altimmune, Inc. (ALT) Misses Q4 EPS by 2c

Altimmune, Inc. (NASDAQ: ALT) reported Q4 EPS of ($0.27), $0.02 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $26 thousand versus the consensus estimate of $625 million.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
• JPMorgan cut off lending activity for Situational Awareness - FT